$THC

KERREY J ROBERT sold $160K of THC

KERREY J ROBERT sold 905 shares of TENET HEALTHCARE CORP (THC) at $176.89 ($0.16M total) on 2026-05-28.

Original reporting
SEC EDGAR · KERREY J ROBERT
Published May 30, 2026, 12:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 30, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The incremental information is the disclosed sale details (date, shares, price, post-transaction holdings). Without accompanying corporate news, the impact is mainly sentiment/positioning rather than fundamentals.

02

Market read

Traders may monitor for follow-on insider activity or any concurrent company-specific catalysts, but this filing by itself is unlikely to reset valuation.

03

What to watch

No 10b5-1 plan is indicated, but the filing alone doesn’t reveal whether the sale was planned, tax-related, or driven by personal liquidity needs; size relative to holdings (17,165 after sale) matters for interpretation.

Relevance 6/10Novelty 6/10Timing: After SEC Form 4 filing/disclosure (filed 2026-05-29; sale dated 2026-05-28)

Background

SEC Form 4 reports insider transactions for Tenet Healthcare; this disclosure covers a director’s open-market sale.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare director KERREY J ROBERT sold 905 shares in an open-market transaction on 2026-05-28 at $176.89/share.

Expected impact

Low-to-mild negative drift possible around the disclosure, but no clear directional catalyst from the filing alone.

Evidence & confidence

The filing is an insider transaction without a 10b5-1 plan and provides a concrete sale price/size; however, insider sales are often routine and typically have limited causal linkage to near-term fundamentals.

Market effects

Minimal; this is company-specific insider activity with no stated operational/regulatory change.

None indicated.

None indicated.

Counterpoint

Because the sale is only 905 shares and not tied to a disclosed corporate event, the market may treat it as diversification or routine liquidity rather than bearish information.

Key entities

  • TENET HEALTHCARE CORP

    Subject of the SEC Form 4 insider transaction disclosure.

  • KERREY J ROBERT

    Director who sold 905 shares of THC on 2026-05-28.

Related articles

$HCAMed

Uninsured patients rise sharply, hospitals report, citing Obamacare cuts | Chattanooga Times Free Press

More and more uninsured patients are showing up in hospital emergency rooms and clinics, having lost their coverage under the Affordable Care Act. Executives running some of the biggest hospital systems, including large for-profit chains spanning many states, expressed concern over the unexpectedly sharp rise in uninsured patients and the costs associated with treating them.

$THCMedAI 8/10

Tenet raises 2026 outlook after weathering ACA headwinds

Tenet Healthcare raised 2026 guidance after Q2 headwinds on Affordable Care Act exchanges. The company now expects adjusted EBITDA of $4.8B to $5.0B, up from $4.5B to $4.8B. Q2 net income rose to $826M on $5.6B revenue, though ACA revenue fell $65M as ACA admissions declined.

$THCHighAI 9/10

Tenet Healthcare Tops Q2 Earnings Estimates, Raises 2026 Outlook

Tenet Healthcare (THC) reported Q2 2026 adjusted EPS of $6.12, 50% above the Zacks Consensus, with net operating revenues up 6.8% to $5.63B. Adjusted net income rose 39.3% to $514M. The company raised 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, and authorized a $2B share repurchase increase.

$THCMedAI 8/10

Why Tenet Healthcare Stock Is Soaring Today

Tenet Healthcare (THC) shares rose after the company reported fiscal Q2 results and raised 2026 guidance. For the quarter ended in June, revenue was $5.63B and adjusted EPS was $6.12, both above year-ago figures and analyst estimates ($5.43B revenue, $4.26 EPS). 2026 revenue guidance increased to $21.9B-$22.5B and adjusted EBITDA to $4.83B-$5.03B.